

The role of cytomegalovirus in prostate cancer incidence and mortality

Johanna Classon¹, Abigail Britten², Kanar Alkass³, Henrik Druid³, Nicole Brenner⁴, Tim Waterboer⁴, Nicholas J Wareham², Effrossyni Gkrania-Klotsas^{2,5*} and Jonas Frisén^{1*}

¹ Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden

² Medical Research Council Epidemiology Unit, University of Cambridge, Cambridge, UK

³ Department of Oncology-Pathology, Karolinska Institutet, Sweden

⁴ Infections and Cancer Epidemiology Division, Deutsches Krebsforschungszentrum, DKFZ, Germany

⁵ Department of Medicine, Cambridge Biomedical Research Centre, Cambridge, UK

* Joint last author

Address correspondence to Jonas Frisén, Jonas.frisen@ki.se and Effrossyni Gkrania-Klotsas, egkraniaklotsas@nhs.net

Keywords: Epidemiology; Cytomegalovirus; Prostate cancer incidence; prostate cancer mortality

Word count text: 5346

Word count abstract: 260

26 **ABSTRACT**

27 Prostate cancer is one of the most common cancers in men with over 350 000 prostate
28 cancer deaths reported worldwide every year. Current risk stratification models are
29 insufficient to predict prostate cancer and prostate cancer death. New biomarkers are
30 needed to identify those at increased risk of lethal prostate cancer. Cytomegalovirus
31 (CMV) infection is common in the healthy prostate epithelium and promotes cell
32 proliferation and viability in prostate cancer. Analyzing matched serum and tissue
33 samples from post-mortem donors (n=41) and prostate cancer patients (n=40), we
34 report that CMV seropositivity predicts high CMV abundance in prostate tissue. We
35 studied if CMV seropositive men had increased prostate cancer incidence and cancer
36 mortality in the European Prospective Investigation of Cancer (EPIC)–Norfolk
37 population-based cohort study. CMV IgG serostatus was determined between 1993
38 and 2000 in 7,655 men aged 40-81 years, of which 57% were CMV seropositive. Study
39 participants were followed for 18±6.0 years (mean±SD). We used Cox proportional
40 hazard models, adjusted for age and potential confounders to estimate hazard ratios
41 (HR) with 95% confidence intervals (CI). CMV serostatus was not associated with
42 prostate cancer incidence (adjusted HR 1.03, 95% CI 0.89-1.19, p=0.687, 138,652
43 person-years). However, among prostate cancer patients, CMV seropositivity was
44 associated with increased risk of prostate cancer-associated mortality (adjusted HR
45 2.26, CI 95% 1.02-4.99, p=0.044, 4639 person-years), with 25% of seropositive and
46 18% of seronegative prostate cancer patients dying from their disease during follow
47 up. These results show that CMV seropositivity is associated with increased risk of
48 prostate cancer death and suggest that CMV infection may contribute to prostate
49 cancer lethality.

50
51
52
53
54
55
56
57
58
59

60 INTRODUCTION

61 Prostate cancer is one of the most common cancers in men with over 350 000 prostate
62 cancer deaths reported worldwide every year¹. Whereas many prostate tumors are
63 indolent, others can develop to metastatic disease, for which there is no cure. Few
64 environmental factors have been linked to prostate cancer development, but the
65 heritability of prostate cancer is 57%², with more than 250 germline single nucleotide
66 variants found to be associated with cancer incidence to date³. In contrast, only few
67 germline events have been identified as risk factors for prostate cancer mortality,
68 including carrying rare mutations in the gene *BRCA2*⁴, and potentially modifiable
69 environmental factors may play a larger role in cancer progression. A probable
70 relationship exists between smoking, obesity and advanced disease and risk for cancer
71 progression, while physical activity might reduce this risk⁵. To date, tools that predict
72 who will develop lethal prostate cancer are insufficient. For example, the commonly
73 used Cancer of the Prostate Risk Assessment (CAPRA) score, which incorporates
74 tumor features, s-PSA and age at diagnosis of localized prostate cancer, moderately
75 predicts cancer-specific mortality (c-index 0.8)⁶. New biomarkers are essential to
76 identify those at risk of lethal prostate cancer.

77
78 Cytomegalovirus (CMV) is a human herpesvirus that establishes chronic infection and
79 globally 83% are seropositive to CMV⁷. However, seroprevalence differs markedly
80 around the world, with western countries having much lower rates than countries in
81 Africa and Asia⁷. CMV infection is present in a large fraction of normal prostate glands,
82 prostate tumors and bone metastases^{8,9}. In a case-control study, CMV serostatus was
83 not associated with prostate cancer incidence, suggesting that CMV does not cause
84 prostate cancer¹⁰. CMV seropositivity is, however, associated with increased all-cause
85 mortality^{11,12}. In the US NHANES III cohort, CMV seropositive men had increased
86 cancer mortality¹³, but it is unknown if CMV serostatus is specifically associated with
87 prostate cancer mortality. We recently reported that local CMV T-cell immunity in the
88 prostate is associated with disease recurrence after radical prostatectomy in carriers
89 of the common allele HLA-A*02-01¹⁴. Moreover, experimental CMV inhibition in
90 models of prostate cancer can induce growth arrest and programmed cell death⁹.

91
92 CMV seropositivity likely underestimates the infected proportion of the population
93 because CMV DNA is often detected along with low abundance of CMV responsive B-

94 and/or T-cells in seronegative individuals¹⁵⁻²⁶. These findings suggest that individuals
95 are infected but have failed to mount a detectable antibody response. In cells of the
96 hematopoietic lineage, CMV is more abundant in CMV seropositive persons, although
97 CMV often is present but at lower levels in individuals without an antibody response²⁷⁻
98 ²⁹. Large interindividual variation exists in abundance of CMV infected epithelial cells
99 in the prostate, ranging from 0-100%⁹, raising the question whether CMV serostatus
100 could also be a marker of CMV abundance in the prostate.

101
102 Here we found that CMV was more abundant in benign prostates and prostate tumors
103 in CMV seropositive compared to CMV seronegative men, demonstrating that CMV
104 seropositivity serves as a marker for widespread CMV infection of the prostate. When
105 we analyzed the large European Prospective Investigation of Cancer (EPIC)-Norfolk
106 population-based cohort study, CMV serostatus was not associated with prostate
107 cancer incidence. However, CMV seropositivity was associated with increased
108 prostate cancer mortality in patients diagnosed with prostate cancer.

109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127

128 **METHODS**

129 **Ethics Statement**

130 Ethical permission for study of human samples was granted by the regional ethics
131 committee of Sweden (2010/313-31/3). Prostate tissue and blood samples were
132 collected from post-mortem donors between 2015 and 2020 through KI Donatum,
133 Karolinska Institutet, Stockholm, Sweden, as described in¹⁴ and⁹; post-mortem cohort.

134
135 De-identified prostate cancer FFPE tissue from prostatectomy specimens with
136 matched plasma (age span 50-68 years of age) was received from the Prostate Cancer
137 Biorepository Network (PCBN) biobank; prostatectomy cohort. Ethical permission for
138 biobank tissue collection was obtained from the local institutional review board at
139 Memorial Sloan Kettering Cancer Center, New York, USA (Protocol #15-025).

140
141 The European Prospective Investigation of Cancer (EPIC)-Norfolk study was approved
142 by the Norwich Local Research Ethics Committee (previously known as Norwich
143 District Ethics Committee) (REC ref: 98CN01; 05/Q0101/191) and Waveney NHS
144 Research Governance Committee (2005EC07L). All participants gave their informed
145 written consent before entering the study. Permission to analyze EPIC-Norfolk data by
146 Swedish researchers was granted by the Swedish Ethical Review Authority, ethical
147 permit number 2021-00457 and its amendment 2022-00965-02.

148
149 **Analyses of CMV immunity in post-mortem and prostatectomy cohorts**

150 We analyzed anti-CMV IgG titers in serum of post-mortem donors and in plasma of
151 prostatectomy prostate cancer patients from PCBN using CMV IgG, CMIA assay
152 (Architect, Abbott, Chicago, Illinois, USA). The cut-off value for a positive assay was
153 6.0 arbitrary units (AU) and measured values up to 250. Samples that had titers of 250
154 or higher were labeled ≥ 250 . Four post-mortem donors were analyzed by CMV IgG
155 chemiluminescence immunoassay on the LIAISON®XL Analyzer. Here >14 was
156 considered positive (U/ml). We determined CMV IgG avidity using human anti-
157 cytomegalovirus IgG ELISA Kit (ab108639, Abcam, Cambridge, UK) using low and
158 high avidity controls (CMV IgG and IgG avidity EIA, DEIA465, Creative Diagnostics,
159 New York, New York, USA). After sample incubation, wells were incubated with either
160 1X wash buffer or 6M urea in 1X wash buffer for 10 minutes. We calculated an index

161 of CMV IgG avidity between non-urea and urea treated wells. High avidity: 0,80-1,00;
162 Intermediate avidity: 0,65-0,79; Low avidity: <0,65.

163
164 Virscan data with Virscores were extracted from¹⁴, in which the analysis was further
165 described, and compared with epithelial CMV-pp71 abundance as analyzed in ⁹. In
166 brief, VirScan is a method to analyze antiviral IgG antibodies by using genetically
167 engineered bacteriophages that display short peptides spanning viral genomes³⁰.
168 Prostate protein lysates were incubated with bacteriophages, IgG-bacteriophage
169 complexes were captured using magnetic beads and sequenced. CMV VirScores,
170 reflecting the number of CMV epitopes recognized by IgG antibodies in a sample, were
171 determined as in³¹. The VirScan method is prone to false positive hits, and CMV
172 VirScore of above five was here considered as CMV VirScore high.

173
174 **Analyses of prostate tissues from post-mortem donors and prostate cancer**
175 **patients**

176 Tissues were processed and analyzed as described in ⁹. Immunohistochemistry
177 protocols and imaging are described in ⁹. This antibody was used: Cytomegalovirus
178 pp71 (goat, 1:200, clone vC-20, sc-33323, polyclonal, Santa Cruz Biotechnology).

179
180 Histological evaluation of prostate cancer and inflammation was assessed in H&E
181 stained FFPE prostate slides by a trained pathologist. Cells with lymphocyte
182 morphology in large and small clusters or spread out in the stroma were classified as
183 chronic inflammation. Acute inflammation with neutrophile infiltration was detected in
184 three prostates in which chronic inflammation was also detected. An incidental prostate
185 cancer (Gleason score 3+3) was detected in a CMV seronegative subject. A suspected
186 incidental prostate cancer was detected in a CMV seropositive subject but was difficult
187 to further assess due to post-mortal effects on the tissue. Two other individuals had
188 been treated for prostate cancer with local radiation and chemotherapy respectively.
189 Medical history was obtained from medical journals, next of kin, police reports and
190 patient registry, all in accordance with ethical permit 2010/313-31/3.

191
192 In prostatectomy samples from PCBN (prostate cancer patients aged 50-68y),
193 Gleason score and pathological T-stage were recorded by pathologists associated with

194 PCBN. Gleason grade groups 1-5 were derived from Gleason scores according to the
195 International Society of Urological Pathology.

196

197 **Statistical analyses of post-mortem and prostatectomy cohorts**

198 All statistical analyses and plots for the cohort with post-mortem donors and the
199 prostatectomy cohort were made in GraphPad prism 8.0 (GraphPad Software, San
200 Diego, California, USA). Two-sided unpaired t-tests were performed on numerical
201 continuous data with normal distribution. Groups with non-normal numerical
202 continuous data was analyzed with Mann-Whitney test. Correlation analyses were
203 performed with Pearson correlation analysis or Spearman correlation analysis when
204 appropriate. Proportions between two groups was analyzed with Fisher's exact test.
205 Non-normal distributed data with more than two groups was compared with Kruskal-
206 Wallis multiple comparisons. Receiver operator characteristic (ROC) curves were
207 constructed and Area under the curve (AUC) calculated using % CMV-pp71 epithelial
208 abundance in CMV IgG- and CMV IgG+ donors or patients. Patients with CMV IgG
209 titers of ≥ 250 were all treated as having CMV IgG titer 250 in analyses.

210

211 **EPIC-Norfolk cohort characteristics**

212 The EPIC-Norfolk study is a prospective population-based cohort in the UK that
213 recruited study participants between 1993 and 1997, aged 40-79 years at time of
214 inclusion. The cohort, with details on methods of data collection and follow up, has
215 previously been described^{12,32}. Participants subjected to CMV serology testing were
216 randomly selected from the EPIC-Norfolk cohort^{12,33}. End of follow-up was 2018 March
217 31st.

218

219 **Serum CMV IgG measurements in the EPIC-Norfolk cohort**

220 In total, 7655 male study participants underwent CMV serology testing. CMV IgG
221 serostatus was determined in serum from blood drawn on 1st health check (1993-1998,
222 n=5894) and/or 2nd health check (1998-2000, n=3846). In blood collected at 1st health
223 check, serum CMV IgG measurements were performed using an indirect
224 chemiluminescence immunoassay (Liaison, Diasorin, Saluggia, Italy). The CMV
225 serology assessment procedure in blood samples collected at 1st health check has
226 previously been described in detail¹². In blood collected at 2nd health check, CMV
227 serostatus was determined by assaying CMV epitopes, performed at the German

228 Cancer Research Center, Heidelberg, Germany, as previously described³⁴. In
229 summary, antibodies against two or more antigens (CMV pp28, CMV pp52, CMV pp65,
230 CMV pp150), with assay values above cut off values determined a priori, were
231 considered as CMV seropositive.

232

233 **Variables collected at baseline in EPIC-Norfolk**

234 Self-reported information on smoking, diabetes mellitus, alcohol usage, Townsend
235 index³⁵, education level, Body Mass Index, Waist-hip ratio, social class, ethnic origin,
236 and marital status were collected at 1st health check (1993-1998).

237

238 **Prostate cancer variables and endpoints in EPIC-Norfolk**

239 Information on prevalent (present at determination of CMV serostatus) and incident
240 prostate cancer (diagnosed after determination of CMV serostatus) was ascertained
241 using ICD-10 code C61 in the UK Cancer Registry until 2016 March 31st, the latest
242 available UK Cancer Registry data. Information on prostate cancer diagnosis,
243 documented using ICD-10 codes 185, C61, was extracted from hospital admission and
244 mortality data until 2018 March 31st. Hospital admissions data include all ICD codes
245 recorded at admissions to hospital, independent of the reason. Prostate cancer
246 diagnosis at hospital admissions is registered as date of admission and not backdated
247 to the date the patient received his diagnosis. Death certificates were obtained for all
248 participants who died before end of follow up at 2018 March 31st. Prostate cancer as
249 underlying cause of death (185, C61) was used as the endpoint prostate cancer
250 mortality.

251

252 Information on prostate cancer stage at diagnosis was documented in the UK cancer
253 register for 284 prostate cancer patients, with 278 being incident prostate cancer
254 cases, divided into general American Joint Committee on Cancer (AJCC) stage groups
255 using TNM classifications. Patients were divided into categories 1-4 and 6, of which
256 category 6 had insufficient information to produce a valid stage. Categories 1-4 were
257 used, which correspond to cancer stage I-IV. Cancer was classified into localized
258 prostate cancer (stage I-II; local growth; T2 or lower, N0, M0) and advanced prostate
259 cancer (stage III-IV; tumor has invaded surrounding tissue and/or presence of lymph
260 node metastases and/or presence of distant metastases; T3 or higher, or N1 or M1).

261

262 **Statistical analyses of EPIC-Norfolk**

263 All analyses of EPIC-Norfolk data were executed in STATA SE 17 (Stata-Corp, College
264 Station, Texas). All data available was included as specified below. No power
265 calculations were conducted prior to this study. All tests of statistical significance were
266 two-sided. P-value below 0.05 was considered statistically significant.

267
268 Characteristics for variables were summarized using mean and standard deviation
269 (SD) for continuous variables and percentages for binary variables. Townsend index
270 was used as a continuous variable, as was alcohol consumption in units per week.
271 Age-adjusted linear regression analyses were performed to compare these variables
272 between CMV seronegative and CMV seropositive males and prostate cancer
273 patients. Binary variables: Prevalent Diabetes Mellitus (0/1), Ever smokers (0/1), Social
274 class: employment and above (0/1), Education; A level and above (0/1; A level
275 corresponds to 12 years of school education in the UK), Marital status; married or not
276 married (0/1), Body Mass Index (≥ 30 or < 30 kg/m²), Waist-Hip ratio (≥ 0.90 or < 0.90 ;
277 according to WHO definitions of high risk Waist-Hip ratio), Ethnic origin Caucasian or
278 non-Caucasian (black Caribbean, black other, Indian, Pakistani, Chinese, Other).
279 Binary variables were compared between CMV seronegative and CMV seropositive
280 males using logistic regression adjusted for age. Data completeness was 97% or
281 higher for all individual variables.

282
283 In time-to-event models, time from serostatus was determined using data from 1st
284 health check or 2nd health check. These two health checks were two years apart. If a
285 participant was CMV seronegative on both 1st health check and 2nd health check, time
286 from CMV serostatus is determined as time from 1st health check. If a participant was
287 seronegative on 1st health check and seropositive on 2nd health check, time from CMV
288 serostatus is determined as time from 2nd health check. If a participant was seropositive
289 on 1st health check and seronegative on 2nd health check, time from CMV serostatus
290 is determined as time from 1st health check (this pattern was observed for a rare
291 number of study participants with CMV serostatus data from both 1st health check and
292 2nd health check; 47/1160: 4.1%). CMV IgG titers are stable over time³⁶. As described
293 in Table S2, CMV seroprevalence in matched age groups was lower in 2nd health check
294 compared to 1st health check, implying that the sensitivity is lower, causing false
295 negative CMV seronegative samples to occur.

296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329

Time to prostate cancer was determined as time to first prostate cancer registration, either in the prostate cancer registry or by registration upon hospital admission. Time from prostate cancer diagnosis to prostate cancer mortality was determined as time from first prostate cancer registration (Figure 2). Censored subjects in time-to-event analyses were either censored due to death from other causes than prostate cancer or were censored at end of study (2018, March 31st).

In time-to-event models, only patients with no missing data were analyzed. Time to event analyses were performed in study participants and patient with \geq two years follow up excluding patients with prevalent prostate cancer. Time-to-event models were performed for all men from time of known serostatus to first prostate cancer registration or prostate cancer death and for prostate cancer patients from time of first registered prostate cancer diagnosis to prostate cancer death (Figure 2). Three time-to-event models were examined: 1) Unadjusted; 2) Adjusted for Age; 3) adjusted for Age, Smoking, Diabetes Mellitus, Body Mass Index, Waist-Hip Ratio, Education level and Townsend index. Assumptions of proportional hazards were examined by Schoenfeld residual statistical measures for each variable. If the assumption of proportional hazards was not fully justified for a variable, it was converted into a time-dependent variable in Cox proportional hazard models.

330 **RESULTS**

331 **Relationship between CMV serostatus and CMV infection in the prostate**

332 We recently reported that chronic CMV infection is common in the prostate using
333 immunoblot, immunohistochemistry (IHC), quantitative PCR and in situ hybridization
334 with the proportion of CMV infected cells in the prostate epithelium ranging from 0-
335 100%⁹. To assess the relationship between CMV infection in the prostate and CMV
336 serostatus, we measured CMV IgG in serum of 41 post-mortem donors aged 19-89 in
337 whom we quantified CMV abundance in the prostate.

338
339 In CMV seropositive post-mortem donors (24/41, 59%), the proportion of the prostate
340 epithelial cells that was infected by CMV ranged from 2% to 100% with a mean of 58%,
341 as assessed by the detection of the CMV protein pp71 by IHC (n=24, Figure 1A). It is
342 well established that CMV infected individuals often are seronegative¹⁵⁻²⁶, and
343 prostates from the 17 CMV seronegative post-mortem donors were all CMV IHC
344 positive, but epithelial abundance of CMV was significantly lower than in CMV
345 seropositive post-mortem donors with a mean of 28% (p<0.0001, Figure 1A).

346
347 We also found a positive association between a high CMV IgG VirScore in prostate
348 tissue^{14,30}, reflecting presence and diversity of CMV IgG antibodies, with CMV-pp71
349 epithelial abundance (n=15, p=0.003) (Figure 1B), further supporting an association
350 between CMV immunity and epithelial CMV infection. Prostates of CMV seropositive
351 donors did not have higher prevalence of inflammatory infiltrates with lymphocytes than
352 in CMV seronegative donors (Figure S1A). Neither was presence of inflammatory
353 infiltrates associated with CMV abundance in CMV seronegative nor CMV seropositive
354 donors (Figure S1B), ruling out general chronic inflammation as a mediator.

355
356 A more pronounced association between CMV serostatus and prostate CMV
357 abundance, determined with CMV-pp71 IHC, was observed in prostate cancer patients
358 who underwent prostatectomy (Prostatectomy cohort). First, 3/10 of prostatectomy
359 samples from CMV seronegative prostate cancer patients had CMV negative tumors
360 and CMV negative benign epithelium (Figure 1C). Second, CMV was commonly found
361 throughout the whole tumor in CMV seropositive patients (Figure 1C, n=10) whereas
362 CMV was less abundant in the tumor in CMV seronegative patients (IgG+ vs IgG-,
363 >90% CMV⁺: p=0.023, n=10 per group, Figure 1C). The median CMV tumor

364 abundance was 99% in CMV seropositive patients (n=10) and 47% in CMV
365 seronegative patients (n=10) (p=0.016; Figure 1C).

366
367 With higher age, titers of anti-CMV IgG antibodies increase, perhaps due to subclinical
368 reactivation events^{28,37}. Prostate CMV abundance is positively correlated with age⁹,
369 but when we analyzed CMV seronegative and CMV seropositive donors separately,
370 CMV abundance only increased with age in CMV seronegative donors (CMV IgG⁻:
371 r=0.72, p=0.001; CMV IgG⁺: r=0.25, p=0.24; Figure S2A). Furthermore, serum CMV
372 IgG titer did not correlate with prostate CMV abundance in CMV seropositive donors
373 (r=0.03, p=0.90, Figure S2B) nor CMV abundance in prostate tumors in CMV
374 seropositive prostate cancer patients (r=0.28, p=0.44, Figure S2C). High avidity of
375 serum CMV IgG antibodies did not further discriminate CMV abundance (Figure S2D).
376 In conclusion, measures of systemic CMV humoral immunity quality (IgG avidity) and
377 quantity (IgG titer) could not be used to discriminate CMV abundance.

378
379 We asked how well CMV serostatus distinguished abundance of CMV in prostate
380 epithelium. Receiver operator characteristic (ROC) analyses showed that CMV
381 seropositivity identifies prostates with higher CMV abundance in post-mortem donors
382 (Area under the curve (AUC): 0.85 (CI 95% 0.73-0.97), p=0.0002) (Figure 1D) and in
383 primary prostate tumors (AUC: 0.81 (CI 95% 0.61-1.00), p=0.0191) (Figure 1E).

384
385 In summary, CMV seropositive men have higher abundance of CMV infected prostate
386 cells than CMV seronegative men. Hence, CMV serostatus is a marker for CMV
387 abundance in benign and malignant prostate tissue.

388 389 **EPIC-Norfolk male CMV cohort characteristics**

390 Next, we asked if CMV infection was associated with prostate cancer incidence or
391 mortality. In order to do so, a large number of prostate specimens or blood samples
392 are required. Since there is often CMV heterogeneity within a prostate, accurate
393 assessment of CMV would entail analyzing large areas, which is difficult to do to in
394 large scale. In contrast, CMV serostatus is analyzed with scalable assays in blood
395 samples.

396

397 We used CMV serostatus to examine if CMV was associated with prostate cancer
398 incidence and mortality (Figure 2A-B). In EPIC-Norfolk, a total of 7655 male
399 participants aged 40-79 years at study recruitment in 1993-1997 were examined for
400 CMV serostatus^{12,33}. CMV serostatus was determined in serum from blood drawn
401 1993-1998 (n=5894) and/or 1998-2000 (n=3846) in males aged 40-81 years. The
402 study participants were followed for 18 ± 6.0 years (mean \pm SD) from blood draw until the
403 end of follow up due to death or end-of-study. Of the study participants, 57% were
404 CMV seropositive on at least one blood test (Table S1, Figure 2). As expected, since
405 CMV seropositivity increases with age³⁸ (Table S2), CMV seronegative participants
406 were on average 2.9 years younger than CMV seropositive participants (58.6 ± 9.1 vs
407 61.5 ± 9.2 years; mean \pm SD) (Table S1). In age-adjusted analyses, CMV seropositive
408 men were more likely to be non-white, smokers, have high BMI, be married, have lower
409 level of education and had addresses in areas of material deprivation, as measured by
410 Townsend index score (Table S1).

411
412 Prostate cancer diagnoses were identified through the UK cancer registry (n=759)
413 and/or by hospital admissions (n=693), identifying a total of 839 prostate cancer
414 patients (Figure S3). Most patients were diagnosed with prostate cancer after CMV
415 serostatus was defined (incident cases, n=783, 93% of all cases) and 219 died from
416 prostate cancer during the study period. Incident prostate cancers were registered
417 11.9 ± 6.0 years after CMV serostatus analysis.

418
419 Twenty prostate cancer patients had their cancer diagnoses registered at the same
420 time as death from the disease, which is likely due to delayed registration of diagnosis.
421 In addition, 11/205 (5.4%) of patients with localized prostate cancer stage at diagnosis
422 in the Cancer Registry died within two years, further substantiating that this error
423 occurs, as the 2-year survival of localized prostate cancer is nearly 100%. To account
424 for this bias, all time to event analyses were performed in study participants and patient
425 with \geq two years follow up.

426 427 **CMV serostatus and prostate cancer incidence**

428 In total, 483 (61.7%) of the men diagnosed with prostate cancer during follow-up were
429 CMV IgG⁺ at the time of blood draw. CMV seropositive men were on average 2.5 years
430 older (mean $76.1\pm$ SD 7.9) than CMV seronegative men (mean $73.6\pm$ SD 7.8) when

431 their incident prostate cancer diagnoses were registered. CMV seropositivity was not
432 associated with increased risk of prostate cancer incidence during follow up in Cox
433 proportional hazard models adjusted for age (HR 0.99, 95% CI 0.85-1.14, $p=0.848$) or
434 smoking, diabetes mellitus, body mass index, waist-hip ratio, education level and
435 Townsend index in addition to age (HR 1.03, 95% CI 0.89-1.19, $p=0.687$) (Table 1).
436 Estimated crude incidence rate ratios (IRR) did not show an association between CMV
437 and prostate cancer incidence (IRR 1.14 95% CI 0.99-1.32, $p=0.068$, 138,652 person-
438 years) (Table S3). In addition, prostate cancer patients aged 50-68 years who
439 underwent prostatectomy (prostatectomy cohort) were not largely CMV seropositive
440 (CMV IgG-: 19/40, CMV IgG+: 21/40, Figure S4A). In conclusion, we find no evidence
441 of a general association between CMV and prostate cancer incidence.

442

443 **CMV and prostate cancer characteristics**

444 We next asked if CMV serostatus is associated with known prognostic prostate cancer
445 features. CMV seropositivity was not more prevalent in patients with advanced
446 compared to localized prostate cancer in EPIC-Norfolk at time of diagnosis ($n=278$,
447 age-adjusted $p=0.487$, advanced prostate cancer CMV seronegative: 31% and CMV
448 seropositive: 27%; localized prostate cancer CMV seronegative: 69% and CMV
449 seropositive: 73%, Table S4). In the prostatectomy cohort ($n=40$), prostate cancer
450 patients had T-stage pT2 or pT3 tumors with varying Gleason scores. CMV
451 seropositivity was not associated with T-stage ($p=0.205$; Fisher's exact test; Figure
452 S4B) nor Gleason grade group ($p=0.078$; Fisher's exact test; Figure S4C). CMV
453 abundance in primary prostate tumors ($n=20$) was not significantly associated with
454 Gleason score (grade group) or T-stage (Figure S4D-E, prostatectomy cohort). In
455 summary, CMV serostatus was not associated with the known prostate cancer
456 prognostic risk factors advanced prostate cancer stage, Gleason score or T-stage at
457 diagnosis, but appears to be an independent parameter.

458

459 **CMV serostatus and prostate cancer mortality**

460 Examining all men in the EPIC-Norfolk cohort, an association between CMV serostatus
461 and prostate cancer mortality was not apparent (adjusted HR 1.24, CI 95% 0.92-1.67,
462 $p=0.166$, $n=7375$, Table 2) but an effect of CMV seropositivity on all-cause mortality
463 adjusted for age and potential confounders was found (adjusted HR 1.10, CI 95% 1.02-

464 1.18, $p=0.019$, $n=7375$, Table 2). Crude incidence rate ratios for all mortality analyses
465 are reported in supplemental Table 7.

466
467 We next examined if CMV serostatus was associated with all-cause and prostate
468 cancer mortality specifically among patients diagnosed with prostate cancer. Of
469 incident prostate cancer patients, CMV seronegative patients were followed for 7.9 ± 4.3
470 years (mean \pm SD) and CMV seropositive patients were followed for 7.6 ± 4.4 years
471 (mean \pm SD) after prostate cancer registration. CMV seropositive prostate cancer
472 patients did not display increased all-cause mortality compared to CMV seronegative
473 prostate cancer patients, as examined in Cox proportional hazard models adjusted for
474 age and other potential confounders (fully adjusted HR 1.17, CI 95% 0.92-1.50,
475 $p=0.206$, $n=588$, Table 2).

476
477 During follow up, 24.7% of CMV seropositive patients and 17.6% of CMV seronegative
478 prostate cancer patients died from their disease. CMV seropositivity was associated
479 with higher risk of prostate cancer mortality in unadjusted (HR 2.47, CI 95% 1.12-5.43,
480 $p=0.024$, $n=597$) and age-adjusted (HR 2.32, CI 95% 1.06-5.13, $p=0.036$, $n=597$) Cox
481 proportional hazard models. The association persisted after adjusting for the potential
482 confounders smoking, diabetes mellitus, body mass index, waist-hip ratio, education
483 level and Townsend index in addition to age (HR 2.26, CI 95% 1.02-4.99, $p=0.044$,
484 $n=588$) (Table 2).

485
486 We conclude that CMV seropositivity, which correlated with higher abundance of
487 CMV in prostate epithelial cells, was associated with increased cancer mortality in
488 prostate cancer patients.

489
490
491
492
493
494
495
496
497

498 **DISCUSSION**

499 We report that CMV infection is more widespread in epithelial cells in the healthy
500 prostate and in prostate cancer in CMV seropositive compared to seronegative men,
501 establishing CMV serostatus as a marker for CMV abundance in the prostate. In a
502 large prospective cohort, CMV serostatus was not associated with prostate cancer
503 incidence, corroborating previous research that found no association between DNA
504 virus immunity and risk of prostate cancer^{10,39,40}. These findings imply that CMV is not
505 an important cause of primary prostate cancer. We, however, report a positive
506 association between CMV seropositivity and prostate cancer mortality in prostate
507 cancer patients, independent of potential confounders such as obesity, smoking and
508 low socioeconomic status.

509
510 Many men who were CMV seronegative still had CMV infected prostates. This is not
511 surprising, as it is well established that CMV serostatus substantially underestimates
512 the proportion of individuals who are infected by CMV¹⁵⁻²². Thus, we are not exclusively
513 comparing groups of individuals who are CMV infected or not, but who are infected to
514 varying degrees. Importantly, this raises the possibility that CMV potentially also may
515 affect prostate cancer mortality in the CMV seronegative group, but to a lesser extent,
516 and that the increased mortality after prostate cancer diagnosis in seropositive prostate
517 cancer patients may underestimate the true effect of CMV. Interestingly, CMV IgG titer
518 in blood could not be used to distinguish prostates with highest CMV abundance.
519 Factors such as age at infection and CMV strain variability may be more important.

520
521 This study has several strengths, including long follow-up time and high data
522 completeness. Furthermore, no study participants were lost during follow up other than
523 due to death prior to study completion. This study also has limitations. Over 99% of
524 study participants were of Caucasian ethnicity, all living in the UK. It is therefore difficult
525 to generalize the study results to other populations such as African American men in
526 USA or men in east Asia, two groups that display increased risk of prostate cancer
527 mortality and have high CMV seroprevalence^{1,7,38,41}. Although excluding participants
528 with less than two years follow up potentially reduced effects of bias introduced by late
529 registration of prostate cancer diagnoses, this strategy may potentially exclude a small
530 fraction of prostate cancer patients diagnosed with *de novo* metastatic prostate cancer
531 with poor outcome.

532

533 CMV seropositivity may be a marker of an altered immune system or of a yet
534 unidentified confounder that could explain the observed associations. Additionally,
535 CMV seropositivity could perhaps select for an earlier death from non-cancer causes
536 and result in selective survival bias, as CMV seropositivity is associated with all-cause
537 mortality and particularly mortality from cardiovascular disease^{11,12}. However, we
538 expect that any possible bias by selective survival is small and would not account for
539 our observations. A main cause of death among prostate cancer patients is
540 cardiovascular disease, and may therefore be a competing risk of death, particularly
541 among CMV seropositive men⁴². An association between CMV serostatus and
542 prostate cancer mortality is not as evident when analyzing all men in our cohort from
543 age of CMV serology, which may relate to the lack of increased incidence and
544 competing hazards.

545

546 The proportion of prostate cancer patients in EPIC-Norfolk diagnosed via s-PSA testing
547 or by showing clinical signs is unknown but could impact study results. CMV
548 seronegative men may be more likely to enroll in s-PSA testing as they in general have
549 higher socioeconomic status than CMV seropositive men (Table S1), which could
550 increase the number of indolent prostate cancer cases in CMV seronegative men.
551 However, adjusting for education level, Townsend index and smoking, among other
552 factors, did not reduce the effect measure of CMV's association with prostate cancer
553 mortality (Table 2). Furthermore, the proportion of patients with advanced cancer
554 disease at diagnosis in EPIC-Norfolk was not dependent on CMV serostatus (Table
555 S3), which suggests that confounding due to different diagnostic intensity is
556 improbable. Rather, trends in EPIC-Norfolk and prostatectomy cohorts suggest that
557 CMV seronegative patients may perhaps be diagnosed with prostate cancer with
558 higher T-stage and Gleason scores than CMV seropositive patients (Table S4, Figure
559 S4B-C). Previous research has shown that there is no association between CMV
560 serostatus and Gleason score¹⁰. The limited information on prostate cancer features
561 and low patient number in our study impede further exploration.

562

563 CMV may drive prostate cancer progression and metastatic spread independent of
564 cellular differentiation (represented by Gleason score) and local invasion (represented
565 by T-stage), perhaps through early seeding. This is in contrast to prostate cancer

566 associated bacteria that may be associated with Gleason score⁴³ and characteristics
567 of advanced disease^{44,45}. This could be due to direct and indirect effects of CMV, For
568 example, CMV-directed T-cells can skew immune responses⁴⁶ and potentially be pro-
569 metastatic. In prostate cancer models, CMV directly promotes cell viability and
570 proliferation⁹, two crucial features of malignant cells that allow tumors to accumulate
571 alterations, perhaps induced by CMV, that result in metastatic disease.

572

573 It will be important to validate the potential of CMV seropositivity as a risk factor for
574 prostate cancer mortality in clinical cohorts, to further examine associations with
575 clinical factors, including treatment modality, s-PSA and family history of prostate
576 cancer. The potential added value of a CMV based assay, such as CMV serology, in
577 prostate cancer prognosis models will be essential to define but was not possible to
578 determine in this study. CMV promotes androgen signaling in prostate cancer and can
579 modulate cellular processes that are associated with resistance to therapies for
580 advanced prostate cancer⁹. It will be important to define if CMV is a predictive marker
581 for the efficiency of anti-androgen therapies. Drugs that target CMV resulted in
582 inhibited growth and induced cancer cell death in CMV infected prostate cancer
583 models⁹. CMV serostatus has the potential to guide treatment choices and direct
584 patient treatment in clinical trials of anti-viral therapies such as maribavir and
585 letermovir⁹, with the hope that these, or other CMV targeted drugs, will prolong survival
586 of prostate cancer patients.

587

588

589

590

591

592

593

594

595

596

597

598

599

600 **ACKNOWLEDGEMENTS**

601 All authors contributed to the study conception, study design, analysis, and
602 interpretation of data. J.C and J.F wrote the manuscript with input from all authors. We
603 thank the MRC Epidemiology Unit for access to data in the EPIC-Norfolk cohort. We
604 thank the Karolinska University Hospital Clinical Microbiology Laboratory where CMV
605 serology assays were performed for post-mortem and prostatectomy cohorts. We
606 thank Professor Hans-Olov Adami and Lars Björnebo for valuable input on the
607 manuscript. J.F and E.GK had full access to all the data in the study and takes
608 responsibility for the integrity of the data and the accuracy of the data analysis.

609

610 **FUNDING**

611 This study was supported by grants from the Swedish Research Council (D0761801),
612 the Swedish Cancer Society (19 0452 Pj, 22 2358 Pj), the Swedish Foundation for
613 Strategic Research (SB16-0014) and Knut och Alice Wallenbergs Stiftelse
614 (2018.0063). The PCBN biobank is supported by the Department of Defense Prostate
615 Cancer Research Program Award No W81XWH-14-2-0182, W81XWH-14-2-0183,
616 W81XWH-14-2-0185, W81XWH-14-2-0186, and W81XWH-15-2-0062 Prostate
617 Cancer Biorepository Network. J.C was supported by the Clinical Scientist Training
618 Program at Karolinska Institutet. E.GK was supported by the NIHR Cambridge
619 Biomedical Research Centre (NIHR203312). The views expressed are those of the
620 authors and not necessarily those of the NIHR or the Department of Health and Social
621 Care.

622

623

624

625

626

627

628

629

630

631

632

633

634 **REFERENCES**

635

- 636 1. Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent Global Patterns in
637 Prostate Cancer Incidence and Mortality Rates. *Eur Urol.* 2020;77(1):38-52.
- 638 2. Mucci LA, Hjelmborg JB, Harris JR, et al. Familial Risk and Heritability of Cancer
639 Among Twins in Nordic Countries. *JAMA.* 2016;315(1):68-76.
- 640 3. Karunamuni RA, Huynh-Le MP, Fan CC, et al. Additional SNPs improve risk
641 stratification of a polygenic hazard score for prostate cancer. *Prostate Cancer*
642 *Prostatic Dis.* 2021;24(2):532-541.
- 643 4. Rawla P. Epidemiology of Prostate Cancer. *World J Oncol.* 2019;10(2):63-89.
- 644 5. Adami H-O, Hunter DJ, Lagiou P, Mucci LA. *Textbook of cancer epidemiology.* Third
645 edition. ed. Oxford ; New York: Oxford University Press; 2018.
- 646 6. Cooperberg MR, Broering JM, Carroll PR. Risk assessment for prostate cancer
647 metastasis and mortality at the time of diagnosis. *J Natl Cancer Inst.*
648 2009;101(12):878-887.
- 649 7. Zuhair M, Smit GSA, Wallis G, et al. Estimation of the worldwide seroprevalence of
650 cytomegalovirus: A systematic review and meta-analysis. *Rev Med Virol.*
651 2019;29(3):e2034.
- 652 8. Samanta M, Harkins L, Klemm K, Britt WJ, Cobbs CS. High prevalence of human
653 cytomegalovirus in prostatic intraepithelial neoplasia and prostatic carcinoma. *J Urol.*
654 2003;170(3):998-1002.
- 655 9. Classon J, Stenudd M, Zamboni M, Alkass K, Eriksson C-J, Pedersen L, Schörling A,
656 Thoss A, Bergh A, Wikström P, Adami H-O, Sørensen HT, Druid H, Frisén J.
657 Cytomegalovirus promotes proliferation and survival of prostate cancer cells and
658 constitutes a therapeutic target. *BioRxiv* 2023;10.1101/2023.10.01.560348
- 659 10. Sutcliffe S, Till C, Gaydos CA, et al. Prospective study of cytomegalovirus serostatus
660 and prostate cancer risk in the Prostate Cancer Prevention Trial. *Cancer Causes*
661 *Control.* 2012;23(9):1511-1518.
- 662 11. Simanek AM, Dowd JB, Pawelec G, Melzer D, Dutta A, Aiello AE. Seropositivity to
663 cytomegalovirus, inflammation, all-cause and cardiovascular disease-related
664 mortality in the United States. *PLoS One.* 2011;6(2):e16103.
- 665 12. Gkrania-Klotsas E, Langenberg C, Sharp SJ, Luben R, Khaw KT, Wareham NJ.
666 Seropositivity and higher immunoglobulin g antibody levels against cytomegalovirus
667 are associated with mortality in the population-based European prospective
668 investigation of Cancer-Norfolk cohort. *Clin Infect Dis.* 2013;56(10):1421-1427.
- 669 13. Okedele OO, Nelson HH, Oyenuga ML, Thyagarajan B, Prizment A. Cytomegalovirus
670 and cancer-related mortality in the national health and nutritional examination
671 survey. *Cancer Causes Control.* 2020;31(6):541-547.
- 672 14. Classon J, Zamboni M, Engblom C, et al. Prostate cancer disease recurrence after
673 radical prostatectomy is associated with HLA type and local cytomegalovirus
674 immunity. *Mol Oncol.* 2022.
- 675 15. Stanier P, Taylor DL, Kitchen AD, Wales N, Tryhorn Y, Tyms AS. Persistence of
676 cytomegalovirus in mononuclear cells in peripheral blood from blood donors. *BMJ.*
677 1989;299(6704):897-898.

- 678 16. Taylor-Wiedeman J, Sissons JG, Borysiewicz LK, Sinclair JH. Monocytes are a major
679 site of persistence of human cytomegalovirus in peripheral blood mononuclear cells.
680 *J Gen Virol.* 1991;72 (Pt 9):2059-2064.
- 681 17. Kraat YJ, Hendrix MG, Wijnen RM, et al. Detection of latent human cytomegalovirus
682 in organ tissue and the correlation with serological status. *Transpl Int.* 1992;5 Suppl
683 1:S613-616.
- 684 18. Zhang LJ, Hanff P, Rutherford C, Churchill WH, Crumpacker CS. Detection of human
685 cytomegalovirus DNA, RNA, and antibody in normal donor blood. *J Infect Dis.*
686 1995;171(4):1002-1006.
- 687 19. Mendelson M, Monard S, Sissons P, Sinclair J. Detection of endogenous human
688 cytomegalovirus in CD34+ bone marrow progenitors. *J Gen Virol.* 1996;77 (Pt
689 12):3099-3102.
- 690 20. Hendrix RM, Wagenaar M, Slobbe RL, Bruggeman CA. Widespread presence of
691 cytomegalovirus DNA in tissues of healthy trauma victims. *J Clin Pathol.*
692 1997;50(1):59-63.
- 693 21. Larsson S, Soderberg-Naucleer C, Wang FZ, Moller E. Cytomegalovirus DNA can be
694 detected in peripheral blood mononuclear cells from all seropositive and most
695 seronegative healthy blood donors over time. *Transfusion.* 1998;38(3):271-278.
- 696 22. Roback JD, Hillyer CD, Drew WL, et al. Multicenter evaluation of PCR methods for
697 detecting CMV DNA in blood donors. *Transfusion.* 2001;41(10):1249-1257.
- 698 23. Loeth N, Assing K, Madsen HO, Vindelov L, Buus S, Stryhn A. Humoral and cellular
699 CMV responses in healthy donors; identification of a frequent population of CMV-
700 specific, CD4+ T cells in seronegative donors. *PLoS One.* 2012;7(2):e31420.
- 701 24. Litjens NHR, Huang L, Dedeoglu B, Meijers RWJ, Kwekkeboom J, Betjes MGH.
702 Protective Cytomegalovirus (CMV)-Specific T-Cell Immunity Is Frequent in Kidney
703 Transplant Patients without Serum Anti-CMV Antibodies. *Front Immunol.*
704 2017;8:1137.
- 705 25. Terlutter F, Caspell R, Nowacki TM, et al. Direct Detection of T- and B-Memory
706 Lymphocytes by ImmunoSpot(R) Assays Reveals HCMV Exposure that Serum
707 Antibodies Fail to Identify. *Cells.* 2018;7(5).
- 708 26. Ashokkumar C, Green M, Soltys K, et al. CD154-expressing CMV-specific T cells
709 associate with freedom from DNAemia and may be protective in seronegative
710 recipients after liver or intestine transplantation. *Pediatr Transplant.*
711 2020;24(1):e13601.
- 712 27. Jackson SE, Sedikides GX, Okecha G, Poole EL, Sinclair JH, Wills MR. Latent
713 Cytomegalovirus (CMV) Infection Does Not Detrimentally Alter T Cell Responses in
714 the Healthy Old, But Increased Latent CMV Carriage Is Related to Expanded CMV-
715 Specific T Cells. *Front Immunol.* 2017;8:733.
- 716 28. Parry HM, Zuo J, Frumento G, et al. Cytomegalovirus viral load within blood increases
717 markedly in healthy people over the age of 70 years. *Immun Ageing.* 2016;13:1.
- 718 29. Slobedman B, Mocarski ES. Quantitative analysis of latent human cytomegalovirus. *J*
719 *Virol.* 1999;73(6):4806-4812.
- 720 30. Xu GJ, Kula T, Xu Q, et al. Viral immunology. Comprehensive serological profiling of
721 human populations using a synthetic human virome. *Science.*
722 2015;348(6239):aaa0698.
- 723 31. Pou C, Nkulikiyimfura D, Henckel E, et al. The repertoire of maternal anti-viral
724 antibodies in human newborns. *Nat Med.* 2019;25(4):591-596.

- 725 32. Day N, Oakes S, Luben R, et al. EPIC-Norfolk: study design and characteristics of the
726 cohort. European Prospective Investigation of Cancer. *Br J Cancer*. 1999;80 Suppl
727 1:95-103.
- 728 33. Gkrania-Klotsas E, Langenberg C, Sharp SJ, Luben R, Khaw KT, Wareham NJ. Higher
729 immunoglobulin G antibody levels against cytomegalovirus are associated with
730 incident ischemic heart disease in the population-based EPIC-Norfolk cohort. *J Infect*
731 *Dis*. 2012;206(12):1897-1903.
- 732 34. Mentzer AJ, Brenner N, Allen N, et al. Identification of host-pathogen-disease
733 relationships using a scalable multiplex serology platform in UK Biobank. *Nat*
734 *Commun*. 2022;13(1):1818.
- 735 35. Phillimore P, Beattie A, Townsend P. Widening inequality of health in northern
736 England, 1981-91. *BMJ*. 1994;308(6937):1125-1128.
- 737 36. Samson LD, van den Berg SP, Engelfriet P, et al. Limited effect of duration of CMV
738 infection on adaptive immunity and frailty: insights from a 27-year-long longitudinal
739 study. *Clin Transl Immunology*. 2020;9(10):e1193.
- 740 37. Komatsu H, Sierro S, A VC, Klenerman P. Population analysis of antiviral T cell
741 responses using MHC class I-peptide tetramers. *Clin Exp Immunol*. 2003;134(1):9-12.
- 742 38. Bate SL, Dollard SC, Cannon MJ. Cytomegalovirus seroprevalence in the United
743 States: the national health and nutrition examination surveys, 1988-2004. *Clin Infect*
744 *Dis*. 2010;50(11):1439-1447.
- 745 39. Korodi Z, Wang X, Tedeschi R, Knekt P, Dillner J. No serological evidence of
746 association between prostate cancer and infection with herpes simplex virus type 2
747 or human herpesvirus type 8: a nested case-control study. *J Infect Dis*.
748 2005;191(12):2008-2011.
- 749 40. Sutcliffe S, Giovannucci E, Gaydos CA, et al. Plasma antibodies against Chlamydia
750 trachomatis, human papillomavirus, and human herpesvirus type 8 in relation to
751 prostate cancer: a prospective study. *Cancer Epidemiol Biomarkers Prev*.
752 2007;16(8):1573-1580.
- 753 41. Mahal BA, Berman RA, Taplin ME, Huang FW. Prostate Cancer-Specific Mortality
754 Across Gleason Scores in Black vs Nonblack Men. *JAMA*. 2018;320(23):2479-2481.
- 755 42. Shikanov S, Kocherginsky M, Shalhav AL, Eggener SE. Cause-specific mortality
756 following radical prostatectomy. *Prostate Cancer Prostatic Dis*. 2012;15(1):106-110.
- 757 43. Banerjee S, Alwine JC, Wei Z, et al. Microbiome signatures in prostate cancer.
758 *Carcinogenesis*. 2019;40(6):749-764.
- 759 44. Hurst R, Meader E, Gihawi A, et al. Microbiomes of Urine and the Prostate Are Linked
760 to Human Prostate Cancer Risk Groups. *Eur Urol Oncol*. 2022.
- 761 45. Pernigoni N, Zagato E, Calcinotto A, et al. Commensal bacteria promote endocrine
762 resistance in prostate cancer through androgen biosynthesis. *Science*.
763 2021;374(6564):216-224.
- 764 46. Moss P. 'From immunosenescence to immune modulation': a re-appraisal of the role
765 of cytomegalovirus as major regulator of human immune function. *Med Microbiol*
766 *Immunol*. 2019;208(3-4):271-280.
- 767
- 768




Figure 1: Relationship between CMV infection in the prostate and CMV serostatus

A) Quantification of percentage CMV-pp71 abundance in prostate areas with epithelial cells in prostate from post-mortem donors. Difference between CMV seronegative (IgG⁻; n=17) and CMV seropositive (IgG⁺; n=24) men was examined with un-paired two-tailed t-test. $p < 0.0001 = ****$. Bar graph shows mean \pm SD. **B)** Abundance of CMV-pp71 (%) in prostates with high prostate CMV IgG VirScore (≥ 6) compared to low CMV IgG VirScore (< 6), n=15, analyzed with un-paired two-tailed t-test. $P < 0.001 = ***$. Bar graph shows mean \pm SD. **C)** Abundance of CMV-pp71 (%) in tumors, determined with IHC, compared between CMV seronegative (IgG⁻; n=10) and CMV seropositive (IgG⁺; n=10) prostate cancer patients with Mann-Whitney test. Bar graph shows mean \pm SD. $P < 0.05 = *$. Analysis underneath graph shows Fisher's exact test of fraction of samples with >90% cancer CMV abundance comparing CMV seropositive (2/10) and seronegative (8/10) patients. **D)** Receiver operator characteristic (ROC) curve for CMV-pp71 epithelial abundance (%) in CMV seropositive post-mortem donors in (A) (in red) compared to CMV seronegative post-mortem donors in (A) (in grey). AUC = Area under the curve. **E)** ROC curve for CMV-pp71 cancer abundance in CMV seropositive prostate cancer patients in (C) (in red) compared to CMV seronegative prostate cancer patients in (C) (in grey). AUC = Area under the curve.




Figure 2: Flow charts of EPIC-Norfolk CMV and prostate cancer study

A) Study design of the EPIC-Norfolk cohort in which CMV serostatus (CMV IgG⁻ vs CMV IgG⁺) and risk of prostate cancer (prostate cancer incidence) was examined. Patients with prevalent prostate cancer and those with less than two years follow up time from CMV serostatus determination to a documented prostate cancer diagnosis were excluded. **B)** Study design of the EPIC-Norfolk cohort in which CMV serostatus (CMV IgG⁻ vs CMV IgG⁺) and risk of overall mortality and prostate cancer mortality was examined. All men in the cohort, excluding patients with prevalent prostate cancer and those with less than two years follow up time from CMV serostatus determination to death were analyzed. Patients with incident prostate cancer with more than two years follow up were examined in independent analyses. Green boxes indicate prostate cancer cases. Red boxes indicate mortality as endpoint in analyses.

	Hazard ratio (CI 95%)	p-value	
Model 1 (Un-adjusted)	1.17 (1.01-1.34)	0.035	n=7427, 778 events
Model 2 (age-adjusted)	0.99 (0.85-1.14)	0.848	n=7427, 778 events
Model 3 (fully adjusted)*	1.03 (0.89-1.19)	0.687	n=7324, 766 events

Table 1: CMV seropositivity and prostate cancer incidence

*Adjusted for Age, Townsend index, Diabetes Mellitus, Body Mass Index, Waist-Hip Ratio, Education level and Smoking. Cox proportional hazard models. CI: Confidence Interval.

	Hazard ratio (CI 95%)	p-value	
All-cause mortality in patients with prostate cancer			
Model 1 (Un-adjusted)	1.35 (1.06-1.72)	0.014	N=597, 288 events
Model 2 (age-adjusted)	1.21 (0.95-1.54)	0.121	N=597, 288 events
Model 3 (fully adjusted)*	1.17 (0.92-1.50)	0.206	N=588, 281 events
Prostate cancer mortality in patients with prostate cancer			
Model 1 (Un-adjusted)	2.47 (1.12-5.43)	0.024	N=597, 130 events
Model 2 (age-adjusted)	2.32 (1.06-5.13)	0.036	N=597, 130 events
Model 3 (fully adjusted)*	2.26 (1.02-4.99)	0.044	N=588, 126 events
All-cause mortality in all men			
Model 1 (Un-adjusted)	1.45 (1.34-1.56)	<0.001	N=7479, 3013 events
Model 2 (age-adjusted)	1.11 (1.03-1.20)	0.006	N=7479, 3013 events
Model 3 (fully adjusted)*	1.10 (1.02-1.18)	0.019	N=7375, 2960 events
Prostate cancer mortality in all men			
Model 1 (Un-adjusted)	1.61 (1.20-2.17)	0.001	N=7479, 199 events
Model 2 (age-adjusted)	1.24 (0.92-1.67)	0.155	N=7479, 199 events
Model 3 (fully adjusted)*	1.24 (0.92-1.67)	0.164	N=7375, 193 events

Table 2: CMV seropositivity, prostate cancer mortality and all-cause mortality

Prostate cancer patients are defined as incident cases, i.e. that their diagnoses are registered after CMV serostatus examination. CMV seropositive patients are compared to CMV seronegative patients. *Adjusted for Age, Townsend index, Diabetes Mellitus, Body Mass Index, Waist-Hip Ratio, Education level and Smoking. Cox proportional hazard models. CI: Confidence Interval.